Procedural Intervention for Benign Prostatic Hyperplasia in Men ≥ Age 70 Years - A Review of Published Literature
- PMID: 37849957
- PMCID: PMC10577238
- DOI: 10.2147/CIA.S414799
Procedural Intervention for Benign Prostatic Hyperplasia in Men ≥ Age 70 Years - A Review of Published Literature
Abstract
Objective: We set out to review studies reporting on the use of surgical intervention to treat Benign Prostatic Hyperplasia in elderly men ≥70 years of age.
Methods: A systematic literature search was conducted using Scopus, PubMed-MEDLINE, Cochrane, and Wiley Online Library databases including studies published between January 2012 through December 2022. This 10-year interval was chosen given the recent plethora of new modalities that have entered the BPH armamentarium, many of which have been marketed as appropriate for older and high-risk patients. The following database search words were used either individually or in conjunction: "BPH", "elderly", "surgical", "ablation", "resection", "embolization", and "aging".
Results: We identified 28 studies for inclusion in this review. The pros and cons of these modalities are presented, specifically as applicable to an older and higher risk population.
Conclusion: There are a wide variety of surgical procedures available for surgically treating BPH in elderly men with varying states of health. Each of these comes with different risks and benefits, supporting that individualized approaches are important. Long-term data and further studies comparing modalities, specifically as regards the elderly and frail, would enhance our approaches to BPH treatment in this patient population.
Keywords: aging; benign prostatic hyperplasia; elderly; surgical.
© 2023 Codelia-Anjum et al.
Conflict of interest statement
Bilal Chughtai is a consultant for Olympus, Boston Scientific, Ferring Pharmaceuticals, and Allergan. Dean Elterman reports grants, personal fees from Boston Scientific, grants from Olympus, grants from Urotronic, grants from Procept Biorobotics, grants from Zenflow, outside the submitted work. Kevin C. Zorn is a consultant and proctor for Boston Scientific, Procept BioRobotics, and investigator for Zenflow. Naeem Bhojani is a consultant for Olympus, Boston Scientific, and Procept BioRobotics. Lori Lerner reports Uncompensated - Chair of the Clinical Events Committee (CEC) from Proverum, outside the submitted work. The authors declare that they have no other known competing interests.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
